Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,458 total articles
Alphabet has climbed back near its highs with a ~$4.02T market cap and a ~$335 share price, but the valuation is getting harder to justify if free cash flow doesn’t re-accelerate. At ~32x earnings and a rich ~55x free cash flow multiple, the market is paying up for an AI-driven upside scenario at the same time momentum is rolling over (bearish MACD…
Strattec Security (STRT) is an overlooked auto supplier trading at modest earnings and low sales multiples despite strong free cash flow generation, low leverage, and improving operational execution. With the stock consolidating below recent highs and valuation still reasonable, the setup favors a defined-risk long trade aimed at a retest of the 52…
Kroger has quietly tightened its narrative around core grocery, leaned into personalization through Google Cloud’s Gemini CX rollout, and backed shareholder returns with a new $2 billion repurchase authorization. With shares near $63.70, improving momentum signals, and a defensive demand profile, KR offers a pragmatic mid-term long setup: defined d…
ClearPoint Neuro sold off hard into $14 despite improving momentum signals and steady liquidity metrics. With the stock sitting near its 50-day average, short interest elevated, and the business positioned around MRI-guided minimally invasive neurosurgery platforms, the risk-reward favors a defined mid-term rebound trade back toward the mid-teens t…
Dyne Therapeutics sits at an interesting intersection for biotech traders: a beaten-down-to-basing chart near $18, meaningful short interest, and a 2026 narrative tied to progress in genetically driven muscle diseases. With liquidity that looks more like a well-funded developer than a fragile microcap, the risk can be framed with a clean stop while…
OPKO Health (OPK) sits in a weird place the market tends to misprice: a sub-$1.1B health services and biopharma hybrid with credible assets, real operating infrastructure, and a long history that has trained investors to shrug. At ~$1.30, the stock is priced like the future is mostly disappointment. But the setup says the opposite is plausible - va…
FLGT has rebounded enough that the stock no longer screams deep value, but valuation is still reasonable for a company with no debt, strong liquidity, and a chart that’s stabilizing. I like a defined-risk long trade into the $30-$31 area, with a tight stop under recent support.
Upstart (UPST) has been treated like a simple consumer-credit grenade, but the market may be overlooking the real asset: a scalable AI underwriting platform that can reaccelerate as risk appetite returns. With the stock near $46, mixed momentum indicators, and short interest still elevated, the setup looks less like a momentum chase and more like a…
Horizon Bancorp trades like a small regional bank the market doesn’t quite trust, but the tape is stabilizing, momentum is improving, and the valuation already prices in a lot of bad news. With margin pressure likely closer to trough than peak, HBNC offers an actionable mid-term long setup with defined risk near support and upside back toward the r…
Dave’s stock is off its highs, momentum is still bearish, and RSI is depressed - but the business metrics underneath look legitimately strong for a fintech this size. With a $2.48B market cap, profitable economics (P/E ~17-18), and meaningful free cash flow, DAVE offers a tactical long setup that targets a rebound back toward key moving averages wh…
Ovid Therapeutics is trying to earn back credibility after a brutal 2024 drawdown, but the setup into early 2026 is cleaner than most: liquid balance-sheet ratios, rising short interest that can fuel upside, and bullish near-term technical momentum. With the stock at $1.74 and still below the $2.01 52-week high, the trade is a mid-term breakout att…
Rigel (RIGL) is trading around $37 after a sharp pullback from its $52.24 52-week high, with momentum still bearish but valuation metrics that look unusually compressed for a profitable biotech. With a ~$671M market cap, ~5.9x P/E, ~2.38x sales, and ~$68.1M in free cash flow, the setup is a fundamentals-backed rebound trade if price can reclaim key…
Angi’s stock is acting like a business that has finally gotten its basics under control: liquidity is solid, valuation is modest, and the chart is starting to cooperate. With elevated short interest and a market cap that implies little confidence in a demand rebound, ANGI sets up as a mid-term trade where “less bad” can be enough. The plan: buy str…
Newmont has rallied hard with gold, yet the stock still screens like a business the market doesn’t fully trust. With gold printing new highs, Newmont’s scale, liquidity, and cash generation matter more than ever. The setup is bullish but extended near fresh 52-week highs, so the trade plan focuses on a controlled entry, clear invalidation, and a re…
VSE has quietly turned M&A into an aerospace aftermarket growth engine, and the stock has priced in a lot of that optimism. With shares near $208 and close to the $218 52-week high, this is less a “buy anytime” setup and more a “buy the dip” trade: wait for a controlled pullback, define risk tightly, and aim for a retest of highs over a 45-trading-…
Apple’s latest surge looks less like a new bull run and more like a relief rally after weeks of headline churn. With momentum still negative on the MACD and the stock below longer-term moving averages, this is a tactical long trade that leans on support near $250 and targets a push back toward the $270 zone if mega-cap earnings sentiment cooperates…
IonQ sold off hard to $44 after trading as high as $50.59, pushing RSI near 39 and leaving the stock below key short-term averages. With short interest elevated and a major acquisition headline in play, the setup favors a defined-risk long aimed at a snapback into the high-$40s/low-$50s, with a tight invalidation below the recent low.
Celestica (CLS) is a buy-the-dip candidate when geopolitical risk-off waves hit high-multiple tech. The stock sits near $308 with a neutral RSI (~50.7) and slightly bearish MACD, but price is holding above key moving averages and liquidity is strong. Fundamentally, CLS is positioned in connectivity/cloud and advanced technology solutions, with a $3…
Pan American Silver (PAAS) hit a new 52-week high at $69.90 and then sold off sharply to $64.88 on heavy volume, a classic momentum reset. The technicals still show bullish momentum (RSI ~76, positive MACD) and the stock sits above key moving averages, setting up a trade into Q4 earnings where operating leverage to silver and gold can translate int…
Bank of Hawaii (BOH) is acting like a regional bank stock that’s finally getting paid for stability. Shares are pushing near the 52-week high on improving technicals and a margin-driven earnings narrative the market tends to reward when rate expectations stabilize. I like a mid-term long with a defined stop below the rising moving averages, aiming …
MercadoLibre is acting well on the tape, with price pushing above major short and intermediate moving averages and bullish MACD momentum. Fundamentals still support the long-term story (e-commerce plus fintech at scale in Latin America), but at ~52x earnings and elevated expectations, the market will punish any margin or cost slippage. This trade i…
AAR Corp. (AIR) has quietly become a market darling in the aviation services complex, riding strong sentiment around defense spending and the expanding aircraft MRO cycle. The problem is the stock is priced like execution risk has been removed, even as free cash flow is currently negative and the chart is pressing into fresh highs with a hot RSI. T…
Bandwidth is a cloud communications software provider where the market is still pricing in “perpetual messiness” despite improving cash generation and a technical backdrop that’s stabilizing. With the stock around $14.41 and trading at roughly 0.58x sales and ~6.6x free cash flow, a mid-term long looks attractive if price can hold recent lows and r…
Microsoft hit my prior upside objective and then pulled back into a technical reset. With MSFT now reclaiming near-term trend levels, MACD momentum turning up, and a major earnings catalyst on deck, I’m upgrading to Strong Buy as a trade idea. The setup is straightforward: defined entry, a stop below the recent swing low, and targets that map to th…
First Citizens BancShares trades at roughly 12x earnings and about 1.17x book at a $25B market cap, which reads as “undervalued” for a top-20 U.S. bank. But price action is still heavy: FCNCA is below its 10- and 20-day averages, RSI is subdued, and MACD remains in bearish momentum. This is a tradeable bounce setup, not a blind value hold - with an…
